N.V. Pizova

Department of Neurology and Medical Genetics with the Course of Neurosurgery SBEI HPE "Yaroslavl State Medical University" of RMPH, Yaroslavl
Chronic fatigue syndrome (CFS) - one of the most common pathologies, the main feature of which is pronounced unmotivated weakness, which eliminates a person from active daily life for a long time. Also, the patient complains of musculoskeletal pain, sleep disturbance, deterioration in short-term memory and concentration, and headache. The modern concepts of the pathogenesis of CFS, and the criteria for its diagnosis are considered. Typical CFS risk factors include poor environmental and health living conditions; frequent and prolonged stress leading to maladjustment; violation of the physiological response to stress; monotonous hard work; lack of exercise with excessive improper nutrition; the lack of prospects in life and a wide range of interests in life. The problems of complex treatment of CFS are discussed.


  1. Beard D.S. Boston Medical and Suxgical J. 1869;3:217–20.
  2. Bell E.J., McCarthey R.A., Riding M.H. J. R. Soc. Med. 1988;81:329–31.
  3. Steele L., Dobbins J. G., Fukuda K., Reyes M., Randall B., Koppelman M., Reeves W.C. The epidemiology of chronic fatigue in San Francisco. Am. J. Med. 1998;105(3) suppl. 1:83S–90S.
  4. Fukuda K., Dobbins J.G., Wilson L.J., Dunn R.A., Wilcox K., Smallwood D. An epidemiologic study of fatigue with relevance for the chro-nic fatigue syndrome. J. Psychiatr. Res. 1997;31(1):19–29.
  5. Jason L.A., Richman J.A., Rademaker A.W., Jordan K.M., Plioplys A.V., Taylor R.R., McCready W., Huang C.F., Plioplys S. A community-based study of chronic fatigue syndrome. Arch. Intern. Med. 1999;159(18):2129–37.
  6. Christley Y., Duffy T., Martin C.R. A review of the definitional criteria for chronic fatigue syndrome. J. Eval. Clin. Pract. 2012;18(1):25–31.
  7. Richman J.A., Flaherty J.A., Rospenda K.M. Chronic fatigue syndrome: have flawed assumptions been derived from treatment-based studies? Am. J. Publ. Health. 1994;84(2):282–84.
  8. Reyes M., Nisenbaum R., Hoaglin D.C., Unger E.R., Emmons C., Randall B., Stewart J.A., Abbey S., Jones J.F., Gantz N., Minden S., Reeves W.C. Prevalence and Incidence of Chronic Fatigue Syndrome in Wichita, Kansas. Arch. Intern. Med. 2003;163:1530–36.
  9. Bakken I., Tveito K., Gunnes N., Ghaderi S., Stoltenberg C., Trogstad L., Hаberg S., Magnus P. Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008–2012. BMC Med. 2014;12(1):167.
  10. Reeves W.C., Jones J.F, Maloney E., Heim C., Hoaglin D.C., Boneva R.S., Morrissey M., Devlin R. Prevalence of Chronic Fatigue Syndrome in Metropolitan, Urban and Rural Georgia. Pop. Health. Metr. 2007;5:5.
  11. Kato K., Sullivan PF., Evengаrd B., Pedersen N.L. Premorbid Predictors of Chronic Fatigue. Arch. Gen. Psych. 2006;63:1267–72.
  12. Heim C., Wagner D., Maloney E., Papanico-laou D.A., Solomon L., Jones J.F., Unger E.R., Reeves W.C. Early Adverse Experience and Risk for Chronic Fatigue Syndrome. Results From a Population-Based Study. Arch. Gen. Psych. 2006;63:1258–66.
  13. Clauw D.J., Chrousos G.P. Chronic pain and fatigue syndromes: overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation. 1997;4:134–53.
  14. Ablashi D.V. Viral studies of CFS. Clin. Infect. Dis. 1994;18:130–32.
  15. Hotopf M.H., Wessely S. Viruses, neurosis and fatigue. J. Psychosom. Res. 1994;38:499–514.
  16. Biswal B., Kunwar P., Natelson B.H. Cerebral blood flow is reduced in chronic fatigue syndrome as assessed by arterial spin labeling. J. Neurol. Sci. 2011;301(1–2):9–11.
  17. Yoshiuchi K., Farkas J., Natelson B.H. Patients with chronic fatigue syndrome have reduced absolute cortical blood flow. Clin. Physiol. Funct. Imaging. 2006;26(2):83–6.
  18. Schmaling K.B. Single-photon emission computerized tomography and neurocognitive function in patients with chronic fatigue syndrome. Psychosom. Med. 2003;65(1):129–36.
  19. Lewis D.H., Mayberg H.S., Fischer M.E., Gold-berg J., Ashton S., Graham M.M., Buchwald D. Monozygotic twins discordant for chronic fatigue syndrome: regional cerebral blood flow SPECT. Radiology. 2001;219(3):766–73.
  20. Mathew S.J., Mao X., Keegan K.A., Levine S.M., Smith E.L., Heier L.A., Otcheretko V., Coplan J.D., Shungu D.C. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T 1H MRS imaging study. NMR Biomed. 2009;22(3):251–58.
  21. Jerjes W.K., Taylor N.F., Wood P.J., Cleare A.J. Enhanced feedback sensitivity to prednisolone in chronic fatigue syndrome. Psychoneuroendocrinology. 2007;32(2):192–98.
  22. Jerjes W.K., Taylor N.F., Peters T.J., Wessely S., Cleare A.J. Urinary cortisol and cortisol metabolite excretion in chronic fatigue syndrome. Psychosom. Med. 2006;68(4):578–82.
  23. Cleare A.J. The HPA axis and the genesis of chronic fatigue syndrome. Trends Endocrinol. Metab. 2004;15(2):55–9.
  24. Chen R., Moriya J., Yamakawa J., Takahashi T., Li Q., Morimoto S., Iwai K., Sumino H., Yamaguchi N., Kanda T. Brain atrophy in a murine model of chronic fatigue syndrome and beneficial effect of Hochu-ekki-to (TJ-41) Neurochem. Res. 2008;33(9):1759–67.
  25. Tang S.W., Chu E., Hui T., Helmeste D., Law C. Influence of exercise on serum brain-derived neurotrophic factor concentrations in healthy human subjects. Neurosci. Lett. 2008;431(1):62–5.
  26. Katafuchi T., Kondo T., Take S., Yoshimura M. Brain cytokines and the 5-HT system during poly I:C-induced fatigue. Ann. N.Y. Acad. Sci. 2006;1088:230–37.
  27. Cleare A.J., Messa C., Rabiner E.A., Grasby P.M. Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and
  28. Yamamoto S., Ouchi Y., Onoe H., Yoshikawa E., Tsukada H., Takahashi H., Iwase M., Yamaguti K., Kuratsune H., Watanabe Y. Reduction of serotonin transporters of patients with chronic fatigue syndrome. Neuroreport. 2004;15(17):2571–74.
  29. Rostene W., Kitabgi P., Parsadaniantz S.M. Chemokines: a new class of neuromodulator? Nat. Rev. Neurosci. 2007;8(11):895–903.
  30. Natelson B.H., Weaver S.A., Tseng C.L., Ottenweller J.E. Spinal fluid abnormalities in patients with chronic fatigue syndrome. Clin. Diagn. Lab. Immunol. 2005;12(1):52–5.
  31. Buchwald D., Komaroff A.L. Review of laboratory findings for patients with chronic fatigue syndrome. Rev. Infect. Dis. 1991;13(1):12–8.
  32. Мороз И.Н., Подколзин А.А. Новое в диаг-ностике и лечении синдрома хронической усталости. Профилактика старения. 1999;1:45–7.
  33. Pagani M., Lucini D. Chronic fatigue syndrome: a hypothesis focusing on the autonomic nervous system. Clin. Sci. (Lond). 1999;96 (1):117–25.
  34. Altura B.M. Basic biochemistry and physiology of magnesium: a brief review. Magnes. Trace Elem. 1991;10:167–71.
  35. Manuel y Keenoy B., Moorkens G., Vertommen J., Noe M., Nuve J., De Leeuw I. Magnesium status and parameters of the oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium. J. Am. Coll. Nutr. 2000;19(3):374–82.
  36. Abraham G., Flechas J. Management of fibromyalgia: Rationale for the use of magnesium and malic acid. J. Nutr. Med. 1992;3:49–59.
  37. Fulle S., Mecocci P., Fano G., Vecchiet I., Vecchi-ni A., Racciotti D., Cherubini A., Pizzigallo E., Vecchiet L., Senin U., Beal M.F. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic. Biol. Med. 2000;29(12):1252–59.
  38. Richards R.S., Roberts T.K., McGregor N.R., Dunstan R.H., Butt H.L. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep. 2000;5(1):35–41.
  39. Logan A.C., Wong C. Chronic fatigue syndrome: oxidative stress and dietary modifications. Altern. Med. Rev. 2001;6(5):450–59.
  40. Manuel y Keenoy B., Moorkens G., Vertommen J., De Leeuw I. Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci. 2001;68(17):2037–49.
  41. Pall M.L., Satterlee J.D. Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and posttraumatic stress disorder. Ann. N.Y. Acad. Sci. 2001;933:323–29.
  42. Fukuda K., Straus S.E., Hickie I., Sharpe MC, Dobbins JG, Komaroff A. The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann. Intern. Med. 1994;121:953–59.
  43. Turnbull N., Shaw E.J, Baker R., Duns­don S., Costin N., Britton G., Kuntze S., Norman R. Chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy): diagnosis and management of chronic fatigue syndrome/myalgic encephalomyelitis (or encephalopathy) in adults and children. London: Royal College of General Practitioners, 2007.
  44. Whiting P., Bagnall A.M., Sowden A.J., Cornell J.E., Mulrow C.D., Ramirez G. Interventions for the Treatment and Management of Chronic Fatigue Syndrome. JAMA. 2001;286:1360–68.
  45. Liptan G., Mist S., Wright C., Artz A., Jones K.D. A pilot study of myofascial release therapy compared to Swedish massage in fibromyalgia. J. Bodyw. Mov. Ther. 2013;17:365–70.
  46. Iannuccelli C., Mannocci F., Guzzo M.P., Olivieri M., Gerardi M.C., Atzeni F., Sarzi-Puttini P., Valesi-ni G., Di Franco M. Complementary treatment in fibromyalgia: combination of somatic and abdominal acupuncture. Clin. Exp. Rheumatol. 2012;30(Suppl. 74):S112–16.
  47. Ogino S., Nagakura Y., Tsukamoto M., Watabiki T., Ozawa T., Oe T., Shimizu Y., Ito H. Systemic administration of 5HT(2C) receptor agonists attenuates muscular hyperalgesia in reserpine-induced myalgia model. Pharmacol. Biochem. Behav. 2013;108:8–15.
  48. Pardini M., Cordano C., Benassi F., Mattei C., Sassos D., Guida S., Serrati C., Primavera A., Amore M., Cocito L., Emberti Gialloreti L. Agomelatine but not melatonin improves fatigue perception: a longitudinal proof-of-concept study. Eur. Neuropsychopharmacol. 2014;24(6):939–44.
  49. Tirelli U., Lleshi A., Berretta M., Spina M., Talamini R., Giacalone A. Treatment of 741 Italian patients with chronic fatigue syndrome. Eur. Rev. Med. Pharmacol. Sci. 2013;17(21):2847–52.

About the Autors

N.V. Pizova – Doctor of Medical Sciences, Professor, Department of Neurology and Medical Genetics with the Course of Neurosurgery SBEI HPE "Yaroslavl State Medical University" of RMPH; e-mail:

Similar Articles

Бионика Медиа